These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23700263)

  • 1. Effects of a sitagliptin safety alert on prescription behaviour for oral antihyperglycaemic drugs: a propensity score-matched cohort study of prescription receipt data in Japan.
    Sato D; Sato Y; Masuda S; Kimura H
    Drug Saf; 2013 Aug; 36(8):605-15. PubMed ID: 23700263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the sitagliptin alert on prescription of oral antihyperglycemic drugs in Japan.
    Sato D; Sato Y; Masuda S; Kimura H
    Int J Clin Pharm; 2012 Dec; 34(6):917-24. PubMed ID: 22941471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial.
    Kobayashi K; Yokoh H; Sato Y; Takemoto M; Uchida D; Kanatsuka A; Kuribayashi N; Terano T; Hashimoto N; Sakurai K; Hanaoka H; Ishikawa K; Onishi S; Yokote K;
    Diabetes Obes Metab; 2014 Aug; 16(8):761-5. PubMed ID: 24447683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride.
    Umayahara R; Yonemoto T; Kyou C; Morishita K; Ogawa T; Taguchi Y; Inoue T
    Endocr J; 2014; 61(12):1163-70. PubMed ID: 25168659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
    Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
    Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.
    Aravind SR; Ismail SB; Balamurugan R; Gupta JB; Wadhwa T; Loh SM; Suryawanshi S; Davies MJ; Girman CJ; Katzeff HL; Radican L; Engel SS; Wolthers T
    Curr Med Res Opin; 2012 Aug; 28(8):1289-96. PubMed ID: 22738801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.
    Dore DD; Seeger JD; Arnold Chan K
    Curr Med Res Opin; 2009 Apr; 25(4):1019-27. PubMed ID: 19278373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004-2013.
    Clemens KK; Liu K; Shariff S; Schernthaner G; Tangri N; Garg AX
    Diabetes Obes Metab; 2016 Jun; 18(6):607-14. PubMed ID: 26939711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
    Srivastava S; Saxena GN; Keshwani P; Gupta R
    J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both glimepiride and high-dose metformin are important for sustained glucose lowering in Japanese type 2 diabetes patients on glimepiride-sitagliptin-metformin therapy: subanalysis of a single-center, open-label, randomized study.
    Arai K; Maeda H; Shirabe S; Yamamoto R; Kumakura A; Yamauchi M; Hirao T; Hirao S; Hirao K
    Diabetes Technol Ther; 2014 Jul; 16(7):442-6. PubMed ID: 24528246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
    Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
    Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan.
    Kimura T; Shiosakai K; Takeda Y; Takahashi S; Kobayashi M; Sakaguchi M
    Pharmaceutics; 2012 Sep; 4(3):479-93. PubMed ID: 24300302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.
    Eurich DT; Simpson S; Senthilselvan A; Asche CV; Sandhu-Minhas JK; McAlister FA
    BMJ; 2013 Apr; 346():f2267. PubMed ID: 23618722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
    Scheller NM; Mogensen UM; Andersson C; Vaag A; Torp-Pedersen C
    Diabetes Obes Metab; 2014 Mar; 16(3):231-6. PubMed ID: 24020750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk.
    Vaduganathan M; Singh A; Sharma A; Januzzi JL; Scirica BM; Butler J; Zannad F; McGuire DK; Cannon CP; Bhatt DL
    Am J Cardiol; 2020 May; 125(10):1577-1581. PubMed ID: 32245636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of antidiabetic drugs in the U.S., 2003-2012.
    Hampp C; Borders-Hemphill V; Moeny DG; Wysowski DK
    Diabetes Care; 2014; 37(5):1367-74. PubMed ID: 24623020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial.
    Al Sifri S; Basiounny A; Echtay A; Al Omari M; Harman-Boehm I; Kaddaha G; Al Tayeb K; Mahfouz AS; Al Elq A; Radican L; Ozesen C; Katzeff HL; Musser BJ; Suryawanshi S; Girman CJ; Davies MJ; Engel SS;
    Int J Clin Pract; 2011 Nov; 65(11):1132-40. PubMed ID: 21951832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.